BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol 2022:S0168-8278(22)00129-5. [PMID: 35271950 DOI: 10.1016/j.jhep.2022.02.022] [Reference Citation Analysis]
2 Burra P, Ferrarese A. Transplanting severely obese cirrhotic patients: Heavy clouds still on the horizon. United European Gastroenterol J 2022. [PMID: 35474616 DOI: 10.1002/ueg2.12234] [Reference Citation Analysis]
3 Pabjan P, Brzdęk M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, Garbat A, Błoniarczyk P, Reczko K, Stępień P, Zarębska-Michaluk D. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals? Viruses 2022;14:96. [PMID: 35062302 DOI: 10.3390/v14010096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lazarus JV, Mark HE, Rinella ME, Colombo M. Editorial: global liver fat accumulation and global health—towards a sustainable development goal. Authors' reply. Aliment Pharmacol Ther 2022;55:489-90. [DOI: 10.1111/apt.16768] [Reference Citation Analysis]
5 Niu L, Thiele M, Geyer PE, Rasmussen DN, Webel HE, Santos A, Gupta R, Meier F, Strauss M, Kjaergaard M, Lindvig K, Jacobsen S, Rasmussen S, Hansen T, Krag A, Mann M. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med 2022. [PMID: 35654907 DOI: 10.1038/s41591-022-01850-y] [Reference Citation Analysis]
6 Byrne CD, Newsome PN, Noureddin M. Why are there no Strategies for NAFLD? J Hepatol 2021:S0168-8278(21)02251-0. [PMID: 34933023 DOI: 10.1016/j.jhep.2021.12.009] [Reference Citation Analysis]
7 Andersson ER. Outside influence: The extrahepatic duct as a source for bile duct regeneration. Hepatology 2022;75:505-7. [PMID: 35006621 DOI: 10.1002/hep.32334] [Reference Citation Analysis]
8 Donnelly MC, Stableforth W, Krag A, Reuben A. The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary. J Hepatol 2022:S0168-8278(22)00118-0. [PMID: 35331574 DOI: 10.1016/j.jhep.2022.02.012] [Reference Citation Analysis]
9 Galatou E, Mourelatou E, Hatziantoniou S, Vizirianakis IS. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 2022;11:1060. [DOI: 10.3390/antiox11061060] [Reference Citation Analysis]
10 Macpherson I, Abeysekera KWM, Harris R, Mansour D, Mcpherson S, Rowe I, Rosenberg W, Dillon JF, Yeoman A. Identification of liver disease: why and how. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101833] [Reference Citation Analysis]
11 Labenz C, Arslanow A, Nguyen-Tat M, Nagel M, Wörns MA, Reichert MC, Heil FJ, Mainz D, Zimper G, Römer B, Binder H, Farin-Glattacker E, Fichtner U, Graf E, Stelzer D, Van Ewijk R, Ortner J, Velthuis L, Lammert F, Galle PR. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL. J Hepatol 2022:S0168-8278(22)00244-6. [PMID: 35472313 DOI: 10.1016/j.jhep.2022.04.009] [Reference Citation Analysis]
12 Antwerpes S, Costa M, Coste M, Bureau M, Maradan G, Cutarella C, Leloutre J, Riccobono-Soulier O, Hedoire S, Frot E, Vernier F, Vassas-Goyard S, Barré T, Casanova D, Carrieri P. Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). Harm Reduct J 2022;19:2. [PMID: 35012570 DOI: 10.1186/s12954-021-00587-0] [Reference Citation Analysis]
13 Donnelly MC, Stableforth W, Krag A, Reuben A. The Negative Bidirectional Interaction Between Climate Change and the Prevalence and Care of Liver Disease: A Joint BSG, BASL, EASL, and AASLD Commentary. Gastroenterology 2022:S0016-5085(22)00149-4. [PMID: 35331440 DOI: 10.1053/j.gastro.2022.02.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Schomerus G, Leonhard A, Manthey J, Morris J, Neufeld M, Kilian C, Speerforck S, Winkler P, Corrigan PW. The stigma of alcohol-related liver disease and its impact on healthcare. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.026] [Reference Citation Analysis]
15 Chapiro J. Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.035] [Reference Citation Analysis]
16 Barré T, Di Marzo V, Marcellin F, Burra P, Carrieri P. Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock? Cannabis Cannabinoid Res 2022. [PMID: 35420457 DOI: 10.1089/can.2022.0014] [Reference Citation Analysis]